RT Journal Article
SR Electronic
T1 Describing the population experiencing COVID-19 vaccine breakthrough following second vaccination in England: A cohort study from OpenSAFELY
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.11.08.21265380
DO 10.1101/2021.11.08.21265380
A1 The OpenSAFELY Collaborative
A1 Amelia Green
A1 Helen Curtis
A1 William Hulme
A1 Elizabeth Williamson
A1 Helen McDonald
A1 Krishnan Bhaskaran
A1 Christopher Rentsch
A1 Anna Schultze
A1 Brian MacKenna
A1 Viyaasan Mahalingasivam
A1 Laurie Tomlinson
A1 Alex Walker
A1 Louis Fisher
A1 Jon Massey
A1 Colm Andrews
A1 Lisa Hopcroft
A1 Caroline Morton
A1 Richard Croker
A1 Jessica Morley
A1 Amir Mehrkar
A1 Seb Bacon
A1 David Evans
A1 Peter Inglesby
A1 George Hickman
A1 Tom Ward
A1 Simon Davy
A1 Rohini Mathur
A1 John Tazare
A1 Rosalind M Eggo
A1 Kevin Wing
A1 Angel Wong
A1 Harriet Forbes
A1 Chris Bates
A1 Jonathan Cockburn
A1 John Parry
A1 Frank Hester
A1 Sam Harper
A1 Ian Douglas
A1 Stephen Evans
A1 Liam Smeeth
A1 Ben Goldacre
YR 2021
UL http://medrxiv.org/content/early/2021/11/08/2021.11.08.21265380.abstract
AB Background While the vaccines against COVID-19 are considered to be highly effective, COVID-19 vaccine breakthrough is likely and a small number of people will still fall ill, be hospitalised, or die from COVID-19, despite being fully vaccinated. With the continued increase in numbers of positive SARS-CoV-2 tests, describing the characters of individuals who have experienced a COVID-19 vaccine breakthrough could be hugely important in helping to determine who may be at greatest risk.Method With the approval of NHS England we conducted a retrospective cohort study using routine clinical data from the OpenSAFELY TPP database of fully vaccinated individuals, linked to secondary care and death registry data, and described the characteristics of those experiencing a COVID-19 vaccine breakthrough.Results As of 30th June 2021, a total of 10,782,870 individuals were identified as being fully vaccinated against COVID-19, with a median follow-up time of 43 days (IQR: 23-64). From within this population, a total of 16,815 (0.1%) individuals reported a positive SARS-CoV-2 test. For every 1000 years of patient follow-up time, the corresponding incidence rate was 12.33 (95% CI 12.14-12.51). There were 955 COVID-19 hospital admissions and 145 COVID-19-related deaths; corresponding incidence rates of 0.70 (95% CI 0.65-0.74) and 0.12 (95% CI 0.1-0.14), respectively. When broken down by the initial priority group, higher rates of hospitalisation and death were seen in those in care homes. Comorbidities with the highest rates of breakthrough COVID-19 included renal replacement therapy, organ transplant, haematological malignancy, and immunocompromised.Conclusion The majority of COVID-19 vaccine breakthrough cases in England were mild with relatively few fully vaccinated individuals being hospitalised or dying as a result. However, some concerning differences in rates of breakthrough cases were identified in several clinical and demographic groups. The continued increase in numbers of positive SARS-CoV-2 tests are concerning and, as numbers of fully vaccinated individuals increases and follow-up time lengthens, so too will the number of COVID-19 breakthrough cases. Additional analyses, aimed at identifying individuals at higher risk, are therefore required.Competing Interest StatementAll authors have completed the ICMJE uniform disclosure form and declare the following: BG has received research funding from Health Data Research UK (HDRUK), the Laura and John Arnold Foundation, the Wellcome Trust, the NIHR Oxford Biomedical Research Centre, the NHS National Institute for Health Research School of Primary Care Research, the Mohn-Westlake Foundation, the Good Thinking Foundation, the Health Foundation, and the World Health Organisation; he also receives personal income from speaking and writing for lay audiences on the misuse of science. IJD holds shares in GlaxoSmithKline (GSK).Funding StatementThis work was supported by the Medical Research Council MR/V015737/1 and the Longitudinal Health and wellbeing strand of the National Core Studies programme. The OpenSAFELY platform is funded by the Wellcome Trust. TPP provided technical expertise and infrastructure within their data centre pro bono in the context of a national emergency.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This study was approved by the Health Research Authority (REC reference 20/LO/0651) and by the LSHTM Ethics Board (reference 21863).I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAccess to the underlying identifiable and potentially re-identifiable pseudonymised electronic health record data is tightly governed by various legislative and regulatory frameworks, and restricted by best practice. The data in OpenSAFELY is drawn from General Practice data across England where TPP is the Data Processor. TPP developers (CB, RC, JP, FH, and SH) initiate an automated process to create pseudonymised records in the core OpenSAFELY database, which are copies of key structured data tables in the identifiable records. These are linked onto key external data resources that have also been pseudonymised via SHA-512 one-way hashing of NHS numbers using a shared salt. DataLab developers and PIs (BG, LS, CEM, SB, AJW, WH, DE, PI, and CTR) holding contracts with NHS England have access to the OpenSAFELY pseudonymised data tables as needed to develop the OpenSAFELY tools. These tools in turn enable researchers with OpenSAFELY Data Access Agreements to write and execute code for data management and data analysis without direct access to the underlying raw pseudonymised patient data, and to review the outputs of this code. All code for the full data management pipeline from raw data to completed results for this analysis and for the OpenSAFELY platform as a whole is available for review at github.com/OpenSAFELY. https://github.com/opensafely/covid-19-vaccine-breakthrough (BMI)Body Mass index(JCVI)Joint Committee Vaccination and Immunisation(IMD)Index of Multiple Deprivation(UK)United Kingdom